Regeneron insider Joseph Lara’s recent buy‑sell pattern signals confidence while adding liquidity, hinting at potential strategic moves for shareholders.
Insider Fenimore’s 2026 Regeneron trades show routine portfolio balancing, not a sell‑off, hinting continued confidence in the biotech’s strong fundamentals.